Investigations regarding the utility of prodigiosenes to treat leukemia.
Prodigiosenes, possessing a 4-methoxypyrrolyldipyrrin skeleton, are known for their anti-cancer activity. Structural modification of the C-ring resulted in a series of prodigiosenes that displayed promising activity against leukemia cell lines during in vitro analysis against the NCI 60 cancer cell line panel. Further in vivo studies of these compounds using the zebrafish model showed persistence of anti-leukemia properties in human K562 chronic myelogenous leukemia cells.
Department of Chemistry, Dalhousie University, Halifax, Nova Scotia B4P 2R6, Canada.
Deborah A
DA
Smithen
A Michael
AM
Forrester
Dale P
DP
Corkery
Graham
G
Dellaire
Julie
J
Colpitts
Sherri A
SA
McFarland
Jason N
JN
Berman
Alison
A
Thompson
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D015394:Molecular Structure; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D011353:Prodigiosin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D011758:Pyrroles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D015027:Zebrafish
D000970:Antineoplastic Agents; D011758:Pyrroles; D011353:Prodigiosin